Breindel H, 2026: A 2026 commentary arguing that ivermectin's in-vitro signal was legitimate but low-confidence, that pharmacokinetic analysis undercut direct antiviral plausibility, and that larger trials found no clinically meaningful benefit.
An initial in vitro antiviral finding generated a legitimate but low-confidence repurposing signal, while subsequent pharmacokinetic and pharmacodynamic analyses substantially constrained the plausibility of direct antiviral efficacy
Breindel H, 2026: A 2026 commentary arguing that ivermectin's in-vitro signal was legitimate but low-confidence, that pharmacokinetic analysis undercut direct antiviral plausibility, and that larger trials found no clinically meaningful benefit. Single-author commentary, no study population. It names the mechanism of the dispute: unstable evidence synthesis, clinical advocacy, public amplification and institutional-distrust narratives. Declarations state no ethics approval needed and disclose AI-assisted drafting. Included because it is the most recent synthesis of the contrary reading and because C5 requires both sides in their own words. Study type: review.
